Showing results (551-560 of 2,319) with videos related to

Sort By:
Pageof 232
Expert Opinion on Therapeutic Targets|April 16, 2024
Potentiation of antidepressant effects: NPY1R agonist and ketamine synergy enhances TrkB signaling and neurogenesis in the ventral hippocampusCarlos Arrabal-Gómez, Pedro Serrano-Castro, Jose Andrés Sánchez-Pérez, et al.
Expert Opinion on Therapeutic Targets|December 14, 2023
How will the identification and therapeutic intervention of genetic targets in oncology evolve for future therapy?Paolo Baldo, Valli De Re, Mattia Garutti
Expert Opinion on Therapeutic Targets|December 19, 2023
Targeting GABA receptors with chalcone derivative compounds, what is the evidence?Feba Benny, Sunil Kumar, Aiswarya Binu, et al.
Expert Opinion on Therapeutic Targets|December 18, 2023
Novel signatures of prostate cancer progression and therapeutic resistanceJason Wang, Reuben Ben-David, Reza Mehrazin, et al.
Expert Opinion on Therapeutic Targets|December 29, 2023
miR-26a-5p restoration via EZH2 silencing blocks the IL-6/STAT3 axis to repress the growth of prostate cancerWenqiang Zhang, Qiwei Nie, Xuling Zhang, et al.
Expert Opinion on Therapeutic Targets|June 25, 2026
Molecular insights for targeting the Nrf1 pathway in hepatocellular carcinomaXi Chen, Zhengwen Zhang, Siqian Cui, et al.
Expert Opinion on Therapeutic Targets|June 25, 2026
The biological role of CCR4 and its ligands CCL17 and CCL22 in atopic dermatitis: therapeutic implications and future directionsDante Dahabreh, Dev Patel, Ester Del Duca, et al.
Expert Opinion on Therapeutic Targets|July 17, 2026
5-FU in combination with PARP inhibitor ABT-888 deregulates MGMT-dependent mismatch repair (MMR) pathway in MMR-proficient colorectal cancer stem cells by modulating MGMT/PARP1/MSH6 complexSubarno Paul, Chinmay Das, Subhasmita Bhal, et al.
Expert Opinion on Therapeutic Targets|July 23, 2026
The PDPK1-RSK2 axis as a potential convergent therapeutic vulnerability in B-cell lymphomasJunya Kuroda, Taku Tsukamoto, Yuji Shimura
Expert Opinion on Therapeutic Targets|July 20, 2026
Tailored strategies to overcome third-generation TKI resistance in EGFR-mutated non-small cell lung cancerIsabella Saporita, Giovanni Farinea, Elisa Lombardi, et al.
Pageof 232